Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy

Cancer Treatment Reviews

Volumn 35, Issue 3, 2009, Pages 289-296

  Schmidinger, Manuela ^a   Zielinski, Christoph C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bevacizumab; Patient selection; Renal cell carcinoma; Side effects; Sunitinib; Temsirolimus; Tolerability

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; INTERFERON; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTERY EMBOLISM; ASTHENIA; BLEEDING; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM METASTASIS; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; EDEMA; FATIGUE; FEVER; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INDIVIDUALIZATION; KIDNEY CARCINOMA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; NAUSEA; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PROGNOSIS; PROTEINURIA; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN DISCOLORATION; SKIN PRURITUS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VEIN EMBOLISM; VOMITING;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; DRUG APPROVAL; DRUG DESIGN; EUROPE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; INDOLES; INTERFERONS; KIDNEY NEOPLASMS; PALLIATIVE CARE; PATIENT SELECTION; PYRROLES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; UNITED STATES;

EID: 64049095783     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.01.004     Document Type: Review

References (56)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. American Cancer Society (ACS). Statistics for 2008. ; 2008 [accessed 30.06.08].
3. Jonasch E., and Haluska F.G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6 (2001) 34-55
4. Margolin K.A. Interleukin-2 in the treatment of renal cancer. Semin Oncol 27 (2000) 194-203
5. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
6. Melichar B., Koralewski P., Ravaud A., et al. First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 19 (2008) 1470-1476
7. Rini B, Halabi S, Rosenberg J, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha monotherapy in metastatic renal cell carcinoma. In: 2008 Genitourinary cancers symposium, 14-16 February, San Francisco, CA; 2008. [abstract 350].
8. Negrier S., Figlin R.A., Hutson T.E., et al. Overall survival with sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma. Ann Oncol 19 8 (2008) viii190 [abstract 588PD]
9. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
10. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
11. Bracarda S., Porta C., Boni C., et al. Randomized prospective phase II trial on two schedules of sorafenib daily and interferon-α2a (IFN-alpha) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681. J Clin Oncol (2007) 26 [abstract 357]
12. Motzer R.J., Escudier B., Oudard S., et al. RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase-III study. J Clin Oncol 26 15S (2008) 1009s [abstract LBA5026]
13. Coppin C., Le L., Porzsolt F., et al. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev (2008) CD006017
14. Escudier B.J., Ravaud A., Négrier S., et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J Clin Oncol 26 15S (2008) 256s [abstract 5025]
15. Dutcher J.P., Szczylik C., Tannir N., et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25 18S (2007) 243s [abstract 5033]
16. Plantade A., Choueiri T., Escudier B., et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. J Clin Oncol 25 18S (2007) 244s [abstract 5037]
17. Plimack E.R., Jonasch E., and Bekele B.N. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): a phase II study. J Clin Oncol 26 15S (2008) 277s [abstract 5112]
18. Choueiri T.K., Plantade A., Elson P., et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26 (2008) 127-131
19. Mydlo J.H., Michaeli J., Cordon-Cardo C., Goldenberg A.S., Heston W.D., and Fair W.R. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 49 (1989) 3407-3411
20. Atlas I., Mendelsohn J., Baselga J., Fair W.R., Masui H., and Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res 52 (1992) 3335-3339
21. Ramp U., Jaquet K., Reinecke P., et al. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J Urol 157 (1997) 2345-2350
22. Perera A.D., Kleymenova E.V., and Walker C.L. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin Cancer Res 6 (2000) 1518-1523
23. Linehan W.M., Pinto P.A., Srinivasan R., et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13 (2007) 671s-679s
24. Pan C., Hussey M., Lara P., et al. Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)-SWOG S0317. J Clin Oncol 25 18S (2007) 651s [abstract15516]
25. Motzer R.J., Figlin R.A., Hutson T.E., et al. Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 25 18S (2007) 241s [abstract 5024]
26. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
27. Bhojani N., Jeldres C., Patard J.J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53 (2008) 917-930
28. Coppin C., Porzsolt F., Awa A., et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) CD001425
29. McDermott D.F., and Atkins M.B. Interleukin-2 therapy of metastatic renal cell carcinoma-predictors of response. Semin Oncol 33 (2006) 583-587
30. Mickisch G.H. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Eur Urol 43 (2003) 670-679
31. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
32. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477
33. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
34. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
35. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721
36. George D.J., Michaelson M.D., Rosenberg J.E., et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. J Clin Oncol 25 (2007) 5035
37. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
38. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26 (2008) 5204-5212
39. Gore M., Szczylik C., Porta C., et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis. Eur J Cancer Suppl 5 (2007) 299
40. Sugrue MM, Kozloff M, Hainsworth J, et al. Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: results from the BRiTE registry. In: 2007 Gastrointestinal cancers symposium, 19-21 January, Orlando, Fl; 2007. [abstract 345].
41. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
42. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
43. Coates A.S., Abraham S.B., Kaye T., et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19 (1983) 203-208
44. Jarernsiripornkul N., Krska J., Capps P.A., et al. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 53 (2002) 318-325
45. Lau P.M., Stewart K., and Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?. Support Care Cancer 12 (2004) 626-633
46. Griffin A.M., Butow P.N., Coates A.S., et al. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7 (1996) 189-195
47. Avastin Summary of Product Characteristics. 25 mg/mL concentrate for solution for infusion 2008.
48. Cloughesy T.F., Prados M.D., Mikkelsen T., et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26 15S (2008) 91s [abstract 2010b]
49. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
50. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
51. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007) 2011-2019
52. Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. In: 2008 Genitourinary cancers symposium, 14-16 February, San Francisco, CA; 2008. [abstract 251].
53. Witteles R.M., Telli M.L., Fisher G.A., et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. J Clin Oncol 26 15S (2008) 526s [abstract 9597]
54. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
55. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
56. Huggins R.H., Kuzel T.M., Anderson R.T., et al. Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL). J Clin Oncol 26 15S (2008) 680s [abstract 16122]